Exploration of Residual Confounding in Analyses of Associations of Metformin Use and Outcomes in Adults With Type 2 Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: Chicago, IL : American Medical Association, [2018]-
    • Subject Terms:
      Metformin*/therapeutic use ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Medicare Part C*; Aged ; Adult ; Female ; Humans ; United States/epidemiology ; Male ; Retrospective Studies ; Insulin, Regular, Human/therapeutic use ; Insulin/therapeutic use
    • Abstract:
      Importance: Metformin is often used as a first-line therapy for type 2 diabetes; however, frequent discontinuation with reduced kidney function and increased disease severity indicates that a comparison with any other group (eg, nonusers or insulin users) must address significant residual confounding concerns.
      Objectives: To examine the potential for residual confounding in a commonly used observational study design applied to metformin and to propose a more robust study design for future observational studies of metformin.
      Design, Setting, and Participants: This retrospective cohort study with a prevalent user design was conducted using an administrative claims database for Medicare Advantage beneficiaries in the US. Participants were categorized into 2 distinct cohorts: 404 458 individuals with type 2 diabetes and 81 791 individuals with prediabetes. Clinical history was observed in 2018, and end points were observed in 2019. Statistical analyses were conducted between May and December 2021.
      Exposures: Prevalent use (recent prescription and history of use on at least 90 of the preceding 365 days) of metformin or insulin but not both at the start of the observation period.
      Main Outcomes and Measures: Total inpatient admission days in 2019 and total medical spending (excluding prescription drugs) in 2019. Each of these measures was treated as a binary outcome (0 vs >0 inpatient days and top 10% vs bottom 90% of medical spending).
      Results: The study included 404 458 adults with type 2 diabetes (mean [SD] age, 74.5 [7.5] years; 52.7% female). A strong metformin effect estimate was associated with reduced inpatient admissions (odds ratio, 0.60; 95% CI, 0.58-0.62) and reduced medical expenditures (odds ratio, 0.57; 95% CI, 0.55-0.60). However, implementation of additional robust design features (negative control outcomes and a complementary cohort) revealed that the estimated beneficial effect was attributable to residual confounding associated with individuals' overall health, not metformin itself.
      Conclusions and Relevance: These findings suggest that common observational study designs for studies of metformin in a type 2 diabetes population are at risk for consequential residual confounding. By performing 2 additional validation checks, the study design proposed here exposes residual confounding that nullifies the initially favorable claim derived from a common study design.
    • References:
      JAMA Surg. 2020 Jun 1;155(6):e200416. (PMID: 32267474)
      Clin Transplant. 2018 Aug;32(8):e13302. (PMID: 29851159)
      Circ Heart Fail. 2011 Jan;4(1):53-8. (PMID: 20952583)
      Diabetes Care. 2021 Jan;44(Suppl 1):S34-S39. (PMID: 33298414)
      Diabetologia. 2020 Feb;63(2):221-228. (PMID: 31853556)
      J Crit Care. 2021 Apr;62:206-211. (PMID: 33422811)
      Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2571-2577. (PMID: 29531023)
      Int J Chron Obstruct Pulmon Dis. 2018 Mar 05;13:793-800. (PMID: 29551895)
      Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: 28693043)
      BMJ Open. 2019 Jul 30;9(7):e024954. (PMID: 31366635)
      Endocr Pract. 2020 Jan;26(1):107-139. (PMID: 32022600)
      Clin Respir J. 2019 May;13(5):299-305. (PMID: 30815978)
      Int J Epidemiol. 2016 Dec 1;45(6):1866-1886. (PMID: 28108528)
      Eur J Clin Invest. 2021 Jul;51(7):e13536. (PMID: 33709434)
      Int J Mol Sci. 2018 Sep 20;19(10):. (PMID: 30241339)
      Ann Am Thorac Soc. 2019 Dec;16(12):1527-1533. (PMID: 31415212)
      Biogerontology. 2019 Feb;20(1):33-48. (PMID: 30255224)
      Diabetologia. 2017 Sep;60(9):1639-1647. (PMID: 28776080)
      Crit Care. 2019 Feb 18;23(1):50. (PMID: 30777119)
      Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420)
      JAMA Ophthalmol. 2021 Mar 1;139(3):302-309. (PMID: 33475696)
      Med Care. 2017 Jul;55(7):698-705. (PMID: 28498196)
      J Diabetes Complications. 2017 Jun;31(6):1007-1013. (PMID: 28416120)
    • Accession Number:
      9100L32L2N (Metformin)
      0 (Insulin, Regular, Human)
      0 (Insulin)
    • Publication Date:
      Date Created: 20221111 Date Completed: 20221115 Latest Revision: 20221208
    • Publication Date:
      20231215
    • Accession Number:
      PMC9652760
    • Accession Number:
      10.1001/jamanetworkopen.2022.41505
    • Accession Number:
      36367726